Sequent Scientific has received prequalification (PQ) approval from the World Health Organization (WHO) for Albendazole, Active Pharmaceutical Ingredient (API). This is in partnership with Mepro Pharmaceuticals, who have successfully developed and commercialised the Albendazole Chewable formulation from its WHO PQ approved plant, using its API. Mepro’s Chewable formulation is the first global approval of its kind by the WHO PQ.
Albendazole is a vital medication used to treat a range of parasitic infections, including tapeworm, roundworm, and hookworm infestations, affecting millions globally, particularly in low and middleincome countries. The WHO prequalification recognizes Sequent Scientific’s commitment to stringent international standards in the production of Albendazole API, ensuring efficacy, safety, and quality.
Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals.
